Effects and Mechanisms of Celecoxib on Intracerebral Hemorrhage
Recruiting
Phase 2
Interventional Study
Intracerebral Hemorrhage
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 20 – 80
- Sex
- Any
- Trial phase
- Phase 2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 60 (estimated)
- Sponsor
- National Taiwan University Hospital · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This trial is a phase IIa human clinical study, in which 60 patients with intracerebral hemorrhage (ICH) at basal ganglion or thalamus within 6 h after onset will be enrolled. Patients will be randomly assigned as treatment group or control group as 1:1 distribution. Early initiation of celecoxib within 6 h after ICH and treatment for 21 days will be performed. The safety will be evaluated by drug…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Acute ICH patients able to take the first dose within 6 hours after onset
* ICH location at basal ganglion or thalamus
* ICH volume \< 30 mL
* Normal renal function (creatinine \[Cr\] ≤ 1.3 mg/dL)
* No surgical indication
* Signed informed consent
* Consciousness clear or mild…
Contacts